Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at Taxoprexin (DHA-paclitaxel) for stomach or oesophageal cancer
This trial was looking at a drug called Taxoprexin for cancer of the stomach or cancer of the food pipe (oesophageal cancer).
If stomach cancer or oesophageal cancer has grown into surrounding tissues, or spread to another part of the body, doctors often treat it with chemotherapy. In this trial, they were looking at a new drug called Taxoprexin. It is made up of a
The aims of the trial were to find out
- How well Taxoprexin worked for advanced stomach or oesophageal cancer
- What the side effects were
Summary of results
The researchers found that Taxoprexin helped some people. When they published their results in 2007, they compared them with results published from other trials. This showed that Taxoprexin worked about as well as other taxane drugs.
The trial recruited people with advanced cancer of the stomach or oesophagus that could not be removed with surgery.
- 53 people had Taxoprexin
- In 5 people, the cancer got smaller – the researchers call this a
- In 35 people, the cancer stayed the same size – researchers call this
- In 8 people, the cancer continued to grow
- The researchers didn’t have results for 5 people
In people who responded to the drug, the trial team looked at the time it took for the cancer to start growing again. On average this was just under 3 months.
The main side effect was a drop in the number of white blood cells, causing an increased risk of infection.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor J Evans